Reduced methylation of MIR145 core promoter is associated with significantly higher risk for disease progression and poor treatment outcome
(A–D) Kaplan-Meier survival curves for the PFS (A) and the DFS (B) of NMIBC patients, as well as the PFS (C) and OS (D) of MIBC patients of the screening cohort according to MIR145 core promoter methylation. (E, F) Kaplan-Meier survival curves for the PFS (E) and OS (F) of the TCGA-BLCA validation cohort according to MIR145 core promoter methylation. p-values calculated by log-rank test. PFS, progression-free survival; DFS, disease-free survival; OS,overall survival; HR, hazard ratio; 95% CI, 95% confidence interval of the estimated HR.